- Home
- OTLK vs AUID Comparison
OTLK vs AUID Comparison
Compare OTLK & AUID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- AUID
- Stock Information
- Founded
- OTLK 2010
- AUID 2009
- Country
- OTLK United States
- AUID United States
- Employees
- OTLK N/A
- AUID N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- AUID Computer Software: Prepackaged Software
- Sector
- OTLK Health Care
- AUID Technology
- Exchange
- OTLK Nasdaq
- AUID Nasdaq
- Market Cap
- OTLK 48.3M
- AUID 47.3M
- IPO Year
- OTLK 2016
- AUID N/A
- Fundamental
- Price
- OTLK $2.34
- AUID $4.48
- Analyst Decision
- OTLK Strong Buy
- AUID
- Analyst Count
- OTLK 5
- AUID 0
- Target Price
- OTLK $9.60
- AUID N/A
- AVG Volume (30 Days)
- OTLK 1.1M
- AUID 65.1K
- Earning Date
- OTLK 08-14-2025
- AUID 08-14-2025
- Dividend Yield
- OTLK N/A
- AUID N/A
- EPS Growth
- OTLK N/A
- AUID N/A
- EPS
- OTLK N/A
- AUID N/A
- Revenue
- OTLK $1,505,322.00
- AUID $2,189,524.00
- Revenue This Year
- OTLK N/A
- AUID N/A
- Revenue Next Year
- OTLK $407.74
- AUID N/A
- P/E Ratio
- OTLK N/A
- AUID N/A
- Revenue Growth
- OTLK N/A
- AUID 295.86
- 52 Week Low
- OTLK $0.87
- AUID $3.38
- 52 Week High
- OTLK $8.32
- AUID $10.21
- Technical
- Relative Strength Index (RSI)
- OTLK 63.83
- AUID 58.46
- Support Level
- OTLK $1.95
- AUID $3.84
- Resistance Level
- OTLK $2.14
- AUID $4.63
- Average True Range (ATR)
- OTLK 0.17
- AUID 0.39
- MACD
- OTLK 0.03
- AUID 0.12
- Stochastic Oscillator
- OTLK 77.62
- AUID 83.32
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.